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1. INTRODUCTION {#mbo3720-sec-0001}
===============

Biofilm is a three‐dimensional structured community of microbial cells that adhere to a biotic or abiotic surface and are enclosed in a self‐produced polymeric matrix (Costerton, Stewart, & Greenberg, [1999](#mbo3720-bib-0010){ref-type="ref"}). Biofilm formation is initiated by adherence of single planktonic cells to a surface, leading to the development microcolonies, which then further grow into mature biofilms that produce components of the extracellular matrix (ECM) to maintain the distinctive structures of cellular aggregates (Hentzer et al., [2003](#mbo3720-bib-0020){ref-type="ref"}). They act as barriers to antimicrobial agents and protect the colonies from any environmental fluctuations. When encased in a biofilm, bacteria can be almost 1,000‐fold more resistant to antibiotics compared with their planktonic counterparts, often rendering the antibiotic therapy ineffective (Chu et al., [2016](#mbo3720-bib-0007){ref-type="ref"}; Drilling et al., [2014](#mbo3720-bib-0013){ref-type="ref"}). This is probably due to the slow growth, metabolic shift, production of ECM, and different cell surface properties of the embedded bacteria (Stryjewski & Corey, [2014](#mbo3720-bib-0039){ref-type="ref"}). According to published reports, over 80% microbial infections in humans are due to biofilms (Musk & Hergenrother, [2006](#mbo3720-bib-0028){ref-type="ref"}).

With the increasing number of immunocompromised patients, the clinical relevance of opportunistic pathogens has increased in recent years. *Pseudomonas aeruginosa* is one of the most important opportunistic human pathogens (Sousa & Pereira, [2014](#mbo3720-bib-0038){ref-type="ref"}). These gram‐negative bacteria kill thousands of people annually and are responsible for 10% of all hospital‐acquired infections (Davies et al., [1998](#mbo3720-bib-0011){ref-type="ref"}). The biofilms of *P. aeruginosa* play a substantial role in cystic fibrosis pneumonia, chronic wound infections, chronic otitis media, chronic bacterial prostatitis, and medical device‐related infections (Rybtke, Hultqvist, Givskov, & Tolker‐Nielsen, [2015](#mbo3720-bib-0035){ref-type="ref"}).

Levofloxacin (OFLX) belongs to a new class of fluoroquinolones, and its activity on *Stretococcus pneumoniae* and other respiratory pathogens has been widely studied and documented (Marchetti & Viale, [2003](#mbo3720-bib-0024){ref-type="ref"}). However, the inhibitory action of OFLX against *P. aeruginosa* biofilms is still controversial due to the different drug concentrations, duration of treatment, and the age of biofilms in different studies. To the best of our knowledge, there is no report so far that evaluates the effect of OFLX on biofilm transcriptomics. We have examined the inhibitory effects of OFLX on the biofilms of *P. aeruginosa* strain PAO1 and clinical isolates by crystal violet (CV) staining and confocal laser scanning microscopy (CLSM), along with the morphological changes in the biofilms associated with OFLX therapy. To determine the potential mechanisms of the antibiofilm effect of OFLX, we analyzed the differentially expressed genes in the biofilms using high‐throughput RNA‐*seq*.

2. MATERIALS AND METHODS {#mbo3720-sec-0002}
========================

2.1. Bacterial strains, growth media, and conditions {#mbo3720-sec-0003}
----------------------------------------------------

Type strain PAO1 (ATCC 15692) used in this study was kindly provided by Mingqiang Qiao (College of Life Sciences of Nankai University, Tianjin, China). And *P. aeruginosa* ATCC 27853 was preserved by our laboratory. The clinical isolates of *P. aeruginosa* were isolated from the patients with pulmonary infections at the third Xiangya Hospital of Central South University (Changsha, Hunan, China) during January 2014 to December 2014 (Qu et al., [2016](#mbo3720-bib-0034){ref-type="ref"}). All of the strains were stored at −80°C in whole milk culture. And Luria‐Bertani (LB) broth (Solarbio, Shanghai, China) was used for bacterial culture in all experiments.

2.2. Materials {#mbo3720-sec-0004}
--------------

OFLX (Aladdin, Shanghai, China) was used and dissolves in distilled water according to the Clinical and Laboratory Standards Institute (CLSI) criteria (2015) (Clinical and Laboratory Standards Institute, [2015](#mbo3720-bib-0009){ref-type="ref"}). The final concentration of OFLX stock solution was 6.4 mg/ml.

2.3. Determination of the minimal inhibitory concentration {#mbo3720-sec-0005}
----------------------------------------------------------

The minimal inhibitory concentration (MIC) was detected by the broth microdilution method as previously described by The CLSI 2015. Briefly, twofold dilutions of OFLX (ranging from 1,024 to 0.0625 μg/ml) were prepared in Mueller‐Hinton broth, and 100 μl was dispensed per well in a 96‐well plate. Each well was then inoculated with 10 μl of *P. aeruginosa* suspension, and the plates were incubated at 35°C for 16\~18 hr. The MIC was determined as the lowest concentration without any visible bacterial growth. McFarland standard 0.5 was used as the reference for turbidity.

2.4. Biofilm‐forming capacity {#mbo3720-sec-0006}
-----------------------------

*Pseudomonas aeruginosa* biofilms were grown according to a previously published protocol (Nesse, Berg, & Vestby, [2015](#mbo3720-bib-0029){ref-type="ref"}). Briefly, an overnight culture of *P. aeruginosa* was diluted 1:200 with LB broth, and 200 μl aliquots were dispensed per well in microplates (Corning/Costar, USA). After 16‐hr incubation at 37°C without shaking, the plates were washed gently with 0.9% saline to remove planktonic cells and then stained with 200 μl 0.25% (w/v) CV solution. After incubation at room temperature for 15 min, the unbound CV was removed with saline, and 200 μl 95% ethanol was added to dissolve the stained dye. Absorbance was measured at 570 nm, and biofilm‐forming capacity was calculated as *A* ~570 nm~. The biofilm‐forming ability was classified according to the criteria of Hassan et al. ([2011](#mbo3720-bib-0019){ref-type="ref"}) (Table [1](#mbo3720-tbl-0001){ref-type="table"}).

###### 

Classification of biofilm production

  Average *A* ~570 nm~ value        Biofilm production
  --------------------------------- --------------------
  ≤*A* ~c~                          Non
  *A* ~c~ \< \~ ≤ 2 × *A* ~c~       Weak
  2 × *A* ~c~ \< \~ ≤ 4 × *A* ~c~   Moderate
  \>4 × *A* ~c~                     Strong

Absorbance cutoff value (*A* ~c~) = average *A* ~570 nm~ of negative control (ATCC27853) + 3 × standard deviation (*SD*) of negative control.

John Wiley & Sons, Ltd

2.5. Biofilm inhibition and eradication assay {#mbo3720-sec-0007}
---------------------------------------------

The biofilm inhibitory assay was performed in microplates as previously described (Qu et al., [2016](#mbo3720-bib-0034){ref-type="ref"}). Briefly, 4 μl overnight culture and 196 μl LB broth were dispensed per well in a 96‐well microplate, and exposed to different concentrations of OFLX. After incubation for 24 hr at 37°C, biofilm biomass was determined by the CV staining method as described. For biofilm eradication (Christensen et al., [1985](#mbo3720-bib-0006){ref-type="ref"}), overnight culture was diluted 1:200 with LB broth, and 100 μl bacterial suspension was dispensed per well in microplates. After static incubation for 24 hr at 37°C, the planktonic cells were removed with saline, and 200 μl LB broth with OFLX was added to each well. After incubation for another 24 hr, biofilm biomass was detected with CV staining.

2.6. CLSM observation {#mbo3720-sec-0008}
---------------------

In order to investigate the biofilm characteristics affected by OFLX, glass slides were placed in six‐well microplates containing 2 ml LB broth with OFLX, and 40 μl overnight culture was added per well. After incubation for 24 hr, the planktonic cells were removed and the biofilms remaining on the glass slides were stained with LIVE/DEAD BacLight Bacterial Viability Kit (Thermo Fisher Scientific, Shanghai, China) as recommended. Briefly, 1.5 μl of SYTO green and PI red dye mix was diluted in 1 ml PBS (pH 7.4), and 100 μl of the dye solution was dropped on each glass slide. After incubation in the dark for 15 min, the glass slides were observed by CLSM (Zeiss LSM 800, Jena, Germany), and the biofilm biomass was quantified with ImageJ software.

2.7. RNA sequencing {#mbo3720-sec-0009}
-------------------

*Pseudomonas aeruginosa* PAO1 was incubated in LB broth with or without 1 μg/ml OFLX (MIC = 2 μg/ml) for 16 hr. After removing the planktonic cells, the biofilms were collected with moist swabs. Three independent biological replicates were used for further analysis. The total RNA was extracted from the biofilms with E.Z.N.A Total RNA Kit II. Subsequent transcriptomic analysis was carried out by the BGI Company. Briefly, sequencing reads' filtering was performed by the SOAPnuke program, and clean reads were mapped to the reference genome of *P. aeruginosa* (RefSeq [NC_002516.2](NC_002516.2)) using HISAT2 program. The StringTie program (version v1.0.4) was then used to the reconstruct the transcripts, and Cuffcompare was used to compare the transcripts and reference annotation. CPC was used to predict the coding potential of the novel transcripts, and differentially expressed genes (DEGs) were determined by DEGseq, DEseq2, PossionDis, NOIseq, and EBseq analysis. Finally, gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway classification analysis were performed to determine the function of the DEGs (Slany, Oppelt, & Cincarova, [2017](#mbo3720-bib-0037){ref-type="ref"}).

2.8. Statistical analysis {#mbo3720-sec-0010}
-------------------------

All experiments were repeated three times to validate the reproducibility. And the data were analyzed by using GraphPad Prism 7.0 software (GraphPad Software, San Diego, CA, USA), and Student\'s *t* test was used to determine the statistical significance of the data. The level of statistical significance was set at *p *\<* *0.05.

3. RESULTS {#mbo3720-sec-0011}
==========

3.1. Effects of OFLX on biofilm formation and eradication {#mbo3720-sec-0012}
---------------------------------------------------------

The effects of OFLX on PAO1 biofilm formation and its eradication are shown in Figure [1](#mbo3720-fig-0001){ref-type="fig"}. Treatment with OFLX at the MIC (2 μg/ml) significantly inhibited PAO1 biofilm formation and continued its inhibitory effect in a dose‐dependent manner (Figure [1](#mbo3720-fig-0001){ref-type="fig"}a). However, higher concentrations of OFLX were needed to eradicate the preformed biofilms. Although biofilms were significantly eradicated by OFLX at 8 μg/ml, there was no significant decrease in the biofilm biomass even at the concentration of 32 μg/ml (Figure [1](#mbo3720-fig-0001){ref-type="fig"}b).

![Antibiofilm activity of OFLX on PAO1. The effects of OFLX on biofilm formation (*n* = 3) (a) and eradication (*n* = 3) (b) at different concentrations, respectively. The data are reported as absorbance at 570 nm (*A* ~570 nm~) of residual biofilm](MBO3-8-e00720-g001){#mbo3720-fig-0001}

3.2. Biofilm‐forming capacity of pulmonary isolates {#mbo3720-sec-0013}
---------------------------------------------------

OFLX tolerance of the biofilms of 30 clinical isolates of *P. aeruginosa*, isolated from the sputum or respiratory tract irrigate of pulmonary infection patients, was tested. CV staining identified five (16.67%) strains as biofilm negative, four (13.33%) as weak, four (13.33%) as moderate, and 17 (56.67%) as strong biofilm producers (Figure [2](#mbo3720-fig-0002){ref-type="fig"}a), which was consistent with the report of Olson et al. ([2002](#mbo3720-bib-0032){ref-type="ref"}). In addition, significant differences were seen among different biofilm‐forming groups by CV staining (Figure [2](#mbo3720-fig-0002){ref-type="fig"}b). Of the 17 strong biofilm producers, four strains (PA01, PA07, PA09, and PA47) were selected for further experiments (Figure [2](#mbo3720-fig-0002){ref-type="fig"}c).

![Biofilm‐forming capacity of *Pseudomonas aeruginosa* pulmonary isolates. Biofilm was formed in microplates at 37°C for 24 hr and stained with crystal violet. (a) Distribution of biofilm production in clinical isolates (*n* = 29). (b) Representative images of biofilm formation by CV staining. (c) Biofilm‐forming ability of strains chosen for our following study. The data are reported as *A* ~570nm~ of residual biofilm](MBO3-8-e00720-g002){#mbo3720-fig-0002}

3.3. Antibiofilm effect of OFLX on pulmonary isolates {#mbo3720-sec-0014}
-----------------------------------------------------

Biofilms of different clinical isolates showed different susceptibility patterns to OFLX. It significantly inhibited the biofilm formation of PA01, PA07, PA09, and PA47 strains at the respective MIC values (2, 0.25, 0.0625, and 0.25 μg/ml for PA01, PA07, PA09, and PA47, respectively; *p *\<* *0.05), as well as in a dose‐dependent manner (Figure [3](#mbo3720-fig-0003){ref-type="fig"}a). PA47 was the strongest biofilm producer among them, but the biofilm of PA01 showed the highest resistance to OFLX. However, biofilms of all strains showed higher resistance to complete eradication by OFLX. It could significantly eradicate the biofilms of PA01, PA07, PA09, and PA47 at the concentrations of 16, 4, and 2 μg/ml, respectively (Figure [3](#mbo3720-fig-0003){ref-type="fig"}b). In addition, the 24‐hr biofilm of PA47 was fully resistant to OFLX even at 128 μg/ml. Finally, there was no significant decrease in the preformed biofilm biomass with increasing concentration of OFLX.

![Antibiofilm effect of OFLX on strong biofilm producers of *P. aeruginosa* clinical isolates. The effects of OFLX at different concentrations on biofilm formation (a) and eradication (b) of *P. aeruginosa* isolated from patients with pulmonary infections. The data are reported as *A* ~570nm~ of residual biofilm](MBO3-8-e00720-g003){#mbo3720-fig-0003}

3.4. Morphological characteristics of *P. aeruginosa* biofilms {#mbo3720-sec-0015}
--------------------------------------------------------------

While the untreated biofilms were thick and relatively homogeneous, treatment with 2 μg/ml OFLX significantly decreased the biofilm biomass and disrupted its structural integrity (Figure [4](#mbo3720-fig-0004){ref-type="fig"}a,c). OFLX could slightly disrupt the integrity of preformed biofilms (Figure [4](#mbo3720-fig-0004){ref-type="fig"}b) and even eradicated the bulk of the biomass to some extent, but living cells remained even at the concentration of 32 μg/ml (Figure [4](#mbo3720-fig-0004){ref-type="fig"}d). In addition, significant morphological alterations were observed in the PAO1 strain and the clinical isolate PA47 following OFLX treatment (Figure [5](#mbo3720-fig-0005){ref-type="fig"}). Rounded or rod‐shaped cells were observed in the untreated sample, while elongated cells with or without swelling appeared in the presence of OFLX.

![CLSM of PAO1 biofilms in the presence of OFLX. Biofilm inhibition (a) and eradication (b) by OFLX at the concentration of 2 and 32 μg/ml, respectively. Then, quantification of total and living biofilm biomass on cover slides in biofilm inhibition assay (c) and eradication assay (d) was performed by ImageJ software. PAO1 grown on cover slides was stained with LIVE/DEAD reagents, and the green (SYTO9) and red (PI) fluorescence indicate viable and dead cells, respectively](MBO3-8-e00720-g004){#mbo3720-fig-0004}

![*Pseudomonas aeruginosa* morphological alteration by OFLX treatment. OFLX elongated the cells of PAO1 and PA47 at the concentration of 16 and 4 μg/ml, respectively. PAO1 grown on cover slides in the presence or absence of OFLX were stained with red fluorescence (PI)](MBO3-8-e00720-g005){#mbo3720-fig-0005}

3.5. OFLX‐inhibited biofilms exhibit a novel transcriptome {#mbo3720-sec-0016}
----------------------------------------------------------

In order to avoid the effect of cell growth inhibition on the expression of mRNA, OFLX at sub‐MIC (1 μg/ml) was chosen for RNA‐*seq* analysis (Figure [6](#mbo3720-fig-0006){ref-type="fig"}). Sequencing analysis revealed significant transcriptional changes in the PAO1 biofilms after a 16‐hr treatment with OFLX (Figure [7](#mbo3720-fig-0007){ref-type="fig"}). The raw expression levels of each sample are shown in the boxplots, and little variability was observed between the samples (Figure [7](#mbo3720-fig-0007){ref-type="fig"}a). A total of 129 differentially expressed genes (DEGs) were seen in the OFLX‐treated biofilms, compared to the untreated control group (Figure [7](#mbo3720-fig-0007){ref-type="fig"}b), of which 86 were upregulated and 43 downregulated (Figure [7](#mbo3720-fig-0007){ref-type="fig"}c). GO function classification analysis was performed to identify alterations in the biological processes (BP), cellular composition (CC), and molecular functions (MF), which revealed that the DEGs were mainly related to metabolic processes (42 DEGs), cellular processes (32 DEGs), single‐organism processes (31 DEGs), molecular binding (39 DEGs), and catalytic activity (39 DEGs) (Figure [7](#mbo3720-fig-0007){ref-type="fig"}d). Furthermore, KEGG pathway classification analysis showed that the DEGs were mainly enriched in the pathways of metabolism, secondary metabolites biosynthesis, quorum sensing, and amino acids biosynthesis (Figure [7](#mbo3720-fig-0007){ref-type="fig"}e).

![Effects of OFLX on planktonic cells growth of PAO1 at the concentration of 1 μg/ml. NS: no statistically significance](MBO3-8-e00720-g006){#mbo3720-fig-0006}

![RNA sequencing analysis. (a) The box plot shows the variations in mRNA expression. (b) Heatmap showing gene expression patterns. (c) Volcano plots of DE genes for PAO1 biofilm formed in response to 1 μg/ml OFLX. And the red, blue, and gray dots indicate upregulated, downregulated, and nonregulated genes, respectively. GO analysis (d) and KEGG pathway classification analysis (e) of upregulated and downregulated genes](MBO3-8-e00720-g007){#mbo3720-fig-0007}

4. DISCUSSION {#mbo3720-sec-0017}
=============

*Pseudomonas aeruginosa* can adhere to the surface of the respiratory tract and form a biofilm, which is considered to be major cause of refractory pulmonary infections such as cystic fibrosis and panbronchiolitis which are very difficult to cure (Cai et al., [2016](#mbo3720-bib-0003){ref-type="ref"}). The bacteria in the biofilms are enclosed in a hydrated matrix of extracellular polymeric substances composed of polysaccharides, nucleic acids, lipids, proteins, etc. (Hoiby, [2017](#mbo3720-bib-0021){ref-type="ref"}). Bacteria within a biofilm are more resistant to antimicrobial agents compared with the planktonic forms (Prosser, Taylor, Dix, & Cleeland, [1987](#mbo3720-bib-0033){ref-type="ref"}), resulting in excess morbidity and mortality as well as higher healthcare costs (Noreddin & Elkhatib, [2009](#mbo3720-bib-0031){ref-type="ref"}). The prevalence of biofilms in pulmonary infection is 83.33%, as a high proportion of *P. aeruginosa* strains are strong biofilm producers.

Fluoroquinolones have been used traditionally against the slow‐growing and nongrowing bacteria (Eng, Padberg, Smith, Tan, & Cherubin, [1991](#mbo3720-bib-0014){ref-type="ref"}), and OFLX has shown a considerable killing effect on *P. aeruginosa* biofilms in experimental studies (Mikuniya et al., [2005](#mbo3720-bib-0025){ref-type="ref"}). In the present study, OFLX significantly inhibited biofilm formation of both PAO1 and respiratory isolates of *P. aeruginosa*, but showed moderate or slight inhibitory effects on the preformed biofilms. In addition, in accordance with the previous studies (Monden, Ando, Iida, & Kumon, [2002](#mbo3720-bib-0026){ref-type="ref"}; Nielsen & Nielsen, [1987](#mbo3720-bib-0030){ref-type="ref"}), the round PAO1 and PA47 cells were elongated in the presence of OFLX. Finally, RNA‐*seq* indicated differential gene expression in PAO1 biofilms upon OFLX treatment.

OFLX interfered with *P. aeruginosa* biofilm synthesis in a dose‐dependent manner. In agreement with our results, Fernández‐Olmos et al. ([2012](#mbo3720-bib-0017){ref-type="ref"}) reported that fluoroquinolones, in particular OFLX, had the most potent effect against the biofilms of *P. aeruginosa* isolates of chronic obstructive pulmonary disease. The findings of Abdi‐Ali, Mohammadi‐Mehr, and Agha Alaei ([2006](#mbo3720-bib-0001){ref-type="ref"}) also support our conclusions. The possible mechanisms of action of OFLX on *P. aeruginosa* biofilms include inhibition of new glycocalyx formation, release, or activation of exopolysaccharide decomposition enzymes, and electrostatic interference with bacterial adhesion (Eng et al., [1991](#mbo3720-bib-0014){ref-type="ref"}). Therefore, OFLX activity on early attached cells might prevent further biofilm development.

However, OFLX had limited inhibitory effect on the preformed and well‐established biofilms. This observation is also consistent with Fernández‐Olmos et al. ([2012](#mbo3720-bib-0017){ref-type="ref"}) who found that higher concentrations of antibiotics were needed to eradicate the preformed biofilms. Our results reaffirm the higher resistance of OFLX in performed biofilms of *P. aeruginosa*. However, it is not easy to maintain such high concentrations of an antibiotic for a considerable length of time in various clinical situations. In addition, the accumulation kinetics of OFLX in biofilm cells is likely more complex compared to that in planktonic cells. The possible mechanisms of the higher resistance of biofilms to OFLX treatment are (a) blocked access of the antibiotic into the embedded bacterial cells by the ECM, (b) partial or complete replacement of the drug‐susceptible population with resistant mutants over time, (c) emergence of persistent cells (Mulcahy, Burns, Lory, & Lewis, [2010](#mbo3720-bib-0027){ref-type="ref"}), and (d) formation of small colony variants (Evans, [2015](#mbo3720-bib-0015){ref-type="ref"}), as well as other unknown resistance mechanisms. Once the antibiotic is removed, the remaining biofilm resumes growth and returns to its initial size (Drago et al., [2011](#mbo3720-bib-0012){ref-type="ref"}).

CLSM showed significant elongation of *P. aeruginosa* cells in the biofilms following OFLX treatment. In a study by Monden et al. ([2002](#mbo3720-bib-0026){ref-type="ref"}), scanning electron microscope, transmission electron microscope, and CLSM were used to investigate the morphological changes in *P. aeruginosa* biofilms in the presence of OFLX and fosfomycin. They also demonstrated a clear OFLX‐induced elongation of the surface biofilm cells, but this change was not clear in the embedded cells. Since fluoroquinolones disrupt the membrane potential or electron transport (Celesk & Robillard, [1989](#mbo3720-bib-0004){ref-type="ref"}), it is possible that changes in the bacterial outer membrane lead to changes in cell wall synthesis and fluidity (Kahan, Kahan, Cassidy, & Kropp, [1974](#mbo3720-bib-0022){ref-type="ref"}). However, little is known about the specific mechanisms and consequences of the shape change in these cells.

*Pseudomonas aeruginosa* biofilms showed significant changes in their transcriptomic profiles after OFLX treatment compared to the untreated cells, with a total of 129 DEGs. Contrary to our expectations, there were only a few of these DEGs that were associated with the well‐known biofilm formation‐related genes like the quorum sensing genes (*lasI/R*,*rlhI/R*,*pqsR et*c.) (Lee & Zhang, [2015](#mbo3720-bib-0023){ref-type="ref"}) and cyclic diguanylate cyclase expression‐associated genes (*siaA* and *siaD*) (Chen et al., [2015](#mbo3720-bib-0005){ref-type="ref"}). Instead, most of the DEGs did not have any specific function. It is possible that instead of a unique influential factor, the inhibitory effects of OFLX on *P. aeruginosa* biofilm synthesis depend on multiple factors. KEGG pathway analysis revealed that the DEGs mainly contributed to metabolic processes, secondary metabolites, and amino acid biosynthesis.

Interestingly, though OFLX showed significant inhibitory effects on biofilm formation, there was more or equal amount of upregulated genes than downregulated genes among these significantly changed pathways. It is possible that the working concentration of OFLX we used was 1 μg/ml. And the sub‐MIC of OFLX used in the transcriptomic analysis resulted in stronger expression of antibiotic resistance‐related genes rather than inhibition of biofilm synthesis‐related genes. Cipriani, Giordano, Magni, Papa, and Filadoro ([1995](#mbo3720-bib-0008){ref-type="ref"}) reported that *P. aeruginosa* showed significant changes in their outer membrane and a 32‐fold increase in MIC values, after a five‐day exposure to sub‐MIC of ciprofloxacin. Similarly, Shun‐Mei et al. ([2018](#mbo3720-bib-0036){ref-type="ref"}) found that after treating *E. coli* with sub‐MIC of OFLX, the antibiotic resistant gene transfer frequency was significantly enhanced by upregulation of conjugation‐associated genes via an SOS‐independent mechanism. In addition, Bhattacharya, Dey, Das, and Banerjee ([2017](#mbo3720-bib-0002){ref-type="ref"}) showed that sub‐MIC levels of antibiotics can lead to resistance and cross‐resistance across several classes of antibiotics in wild strains of *S. aureus*, possibly by free radical production. Finally, Gupta, Chhibber, and Harjai ([2016](#mbo3720-bib-0018){ref-type="ref"}) found that sub‐MIC of ciprofloxacin could inhibit *P. aeruginosa* biofilm formation and virulence factor production by targeting the QS system. However, in our study, the QS‐related pathway was significantly upregulated in the presence of sub‐MIC OFLX, indicating different mechanisms of inhibiting *P. aeruginosa* biofilm formation by ciprofloxacin and OFLX at sub‐MIC, though both are fluoroquinolones.

In summary, OFLX can inhibit *P. aeruginosa* biofilm synthesis in a dose‐dependent manner, but cannot fully eradicate the preformed biofilms even at high concentrations. In addition, 1 μg/ml OFLX significantly altered the expression of PAO1 genes related to metabolic processes, cellular processes, single‐organism processes, molecular binding, and catalytic activity. Our data can help determine the optimum OFLX concentration needed for biofilm inhibition and eradication of *P. aeruginosa* infection.
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